Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03833180
Other study ID # 2140-001
Secondary ID VLS-101-0001
Status Completed
Phase Phase 1
First received
Last updated
Start date March 14, 2019
Est. completion date December 18, 2023

Study information

Verified date January 2024
Source VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated hematological cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), Burkitt lymphoma (BL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), lymphoplasmacytoid lymphoma/Waldenström macroglobulinemia (LPL/WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Richter transformation lymphoma (RTL), and T-cell non-Hodgkin lymphoma (NHL).


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date December 18, 2023
Est. primary completion date December 18, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men or women of age =18 years. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. - Histological diagnosis of CLL/SLL, MCL, FL, MZL, DLBCL, RTL, BL, LPL/WM, T-cell NHL, ALL, or AML as documented in medical records. - Hematological cancer under study has been previously treated and has progressed during or relapsed after prior systemic therapy. - Hematological cancer is unlikely to be responsive to established therapies known to provide clinical benefit or the study candidate has developed an intolerance to established therapies known to provide clinical benefit. - Presence of measurable cancer including CLL/SLL, MCL, FL, MZL, DLBCL, RTL, BL, LPL/WM, T-cell NHL, ALL, and AML. - Current medical need for therapy due to disease-related symptoms or complications, cytopenias, lymphadenopathy, organomegaly, extranodal organ involvement, or progressive disease. - Availability of pretreatment tumor tissue. - Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer =1 week before the start of study therapy. - All acute toxic effects of any prior antitumor therapy (not including hydroxyurea, cytarabine, and/or cyclophosphamide used in subjects with acute leukemia) resolved to =Grade 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted] or selected laboratory parameters [Grade 1 or Grade 2 permitted with exceptions. - Adequate bone marrow function. - Adequate hepatic profile. - Adequate renal function. - Adequate coagulation profile. - Negative antiviral serology. - For female participants of childbearing potential, a negative serum pregnancy test. - For both male and female participants, willingness to use protocol-recommended method of contraception from the start of the screening period until =6 months after the final dose of study therapy. - Willingness and ability of the participant to comply with study activities. - Evidence of a personally signed informed consent document. - Previous treatment with an MMAE-containing drug is allowed. Exclusion Criteria: - Presence of malignancy involving the central nervous system. - Presence of another cancer with disease manifestations or therapy that could adversely affect participant safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results. - Significant cardiovascular disease within 3 months prior to start of study therapy. - Significant screening electrocardiogram (ECG) abnormalities. - Uncontrolled ongoing systemic bacterial, fungal, or viral infection. - Known diagnosis of liver cirrhosis. - Pregnancy or breastfeeding. - Candidacy for hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR)-T-cell therapy with access to HSCT or CAR-T cells and a willingness to undergo such therapy. - In participants with prior HSCT, evidence of graft-versus-host disease (GVHD) with Grade =2 serum bilirubin, Grade =3 skin involvement, or Grade =3 diarrhea. - Prior solid organ transplantation. - Major surgery within 4 weeks before the start of study therapy. - Prior therapy with a receptor tyrosine kinase-like orphan receptor 1 (ROR1)-directed therapy. - Has ongoing corticosteroid therapy (exceeding 30 mg daily of prednisone equivalent). Prednisone equivalent dosing must have been stable for at least 4 weeks prior to Cycle 1 Day 1 (C1D1). If corticosteroid treatment is required for lymphoma symptom control prior to C1D1, up to 100 mg per day of prednisone equivalent can be given for up to 5 days. In that case, all tumor assessments must have been completed prior to the start of corticosteroid treatment. - Use of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4. - Use within 7 days prior to the start of study therapy of a drug known to prolong the QT interval. - Concurrent participation in another therapeutic or imaging clinical trial. - Presence of a medical condition that (in the judgement of the investigator) interferes with the ability of the participant to participate in the study. - Has baseline peripheral neuropathy >Grade 1.

Study Design


Intervention

Drug:
Zilovertamab vedotin
Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.

Locations

Country Name City State
United States University of Virginia Cancer Center ( Site 0012) Charlottesville Virginia
United States City of Hope ( Site 0010) Duarte California
United States MD Anderson Cancer Center ( Site 0001) Houston Texas
United States MD Anderson Cancer Center ( Site 0011) Houston Texas
United States University of California - San Diego ( Site 0003) La Jolla California
United States UCLA Hematology & Oncology ( Site 0007) Los Angeles California
United States Northwell Health ( Site 0009) New Hyde Park New York
United States Memorial Sloan Kettering Cancer Center ( Site 0014) New York New York
United States Weill Cornell Medical College ( Site 0005) New York New York
United States University of Nebraska Medical Center ( Site 0006) Omaha Nebraska
United States Oregon Health & Science University ( Site 0004) Portland Oregon
United States University of Rochester ( Site 0008) Rochester New York
United States Swedish Medical Center ( Site 0002) Seattle Washington
United States Memorial Sloan-Kettering Cancer Center ( Site 0019) Uniondale New York

Sponsors (1)

Lead Sponsor Collaborator
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wang ML, Barrientos LC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K, Kipps TJ, Rule S, Flanders K, Jessen KA, Ren H, Riebling PC, Graham P, King L, Thurston AW, Sun M, Schmidt EM, Lannutti BJ, Johnson DM, Miller LL, Spurgeon SE. Zilove

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) of zilovertamab vedotin Participants will receive zilovertamab vedotin according to Schedule 1, 2, or 3. The MTD will be determined by the number of participants who experience a dose limiting toxicity (DLT). The MTD will be defined as the highest tested dose level at which =6 participants have been treated and which is associated with a Cycle 1 DLT in =17% of the participants. Cycle 1 (Up to 21 Days)
Primary Recommended Dosing Regimen (RDR) Selection of the RDR will be based on consideration of short- and long-term safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The RDR may be the MTD or may be a lower dose within the tolerable dose range. Cycle 1 (Up to 21 Days)
Secondary Average number of zilovertamab vedotin infusions administered Zilovertamab vedotin drug administration will be assessed by prescribing records and the average number of zilovertamab vedotin infusions administered will be determined. Up to 5 months
Secondary Number of participants with a treatment-emergent adverse event (TEAE) An AE is any untoward medical occurrence in a participant administered a medicinal product; the event does not necessarily have a causal relationship with study drug administration or usage. Laboratory abnormalities, vital sign/oxygen saturation abnormalities, and adverse electrocardiogram (ECG) findings will also be recorded as AEs. A TEAE is defined as an AE that occurs or worsens in the period from the first dose of study drug administration to 30 days after the final dose of study drug administration. The number of participants with a TEAE will be reported for each arm. Up to approximately 3.5 years
Secondary Number of participants with a DLT A DLT is defined as a protocol pre-specified TEAE that occurs in Cycle 1 of zilovertamab vedotin therapy and is considered drug-related. Failure to recover to baseline by =21 days from the last dose of study drug in the current cycle due to a drug-related TEAE is also considered a DLT. The number of participants with a DLT will be reported for each arm. Cycle 1 (Up to 21 Days)
Secondary Number of participants with a serious adverse event (SAE) An SAE is defined as an untoward medical occurrence that results in any of the following outcomes: death, life-threatening situation, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or other medically significant event. Up to approximately 3.5 years
Secondary Number of participants with an adverse event of special interest (AESI) Prespecified AESIs for this study will include: Grade =3 infusion reactions, tumor lysis syndrome (TLS) of any grade, and Grade =3 peripheral neuropathy. The number of participants with an AESI will be reported for each arm. Up to approximately 3.5 years
Secondary Number of participants that discontinue study treatment due to an AE An AE is any untoward medical occurrence in a participant administered a medicinal product; the event does not necessarily have a causal relationship with study drug administration or usage. The number of participants that discontinue study treatment due to an AE will be reported for each arm. Up to approximately 3.5 years
Secondary Number of participants that use supportive care or concomitant medications The number of participants that use supportive care or concomitant medications will be reported for each arm. Up to approximately 3.5 years
Secondary Plasma concentration of zilovertamab vedotin Plasma concentration of zilovertamab vedotin will be reported for each arm. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Plasma concentration of total UC-961 antibody Plasma concentration of total UC-961 antibody will be reported for each arm. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Plasma concentration of monomethyl auristatin E (MMAE) Plasma concentration of MMAE will be reported for each arm. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Maximum plasma concentration (Cmax) of zilovertamab vedotin Blood samples collected predose and at multiple timepoints postdose will be used to determine Cmax of zilovertamab vedotin. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Time to maximum plasma concentration (Tmax) of zilovertamab vedotin Blood samples collected predose and at multiple timepoints postdose will be used to determine Tmax of zilovertamab vedotin. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Area under the plasma concentration time curve (AUC) of zilovertamab vedotin Blood samples collected predose and at multiple timepoints postdose will be used to determine AUC of zilovertamab vedotin. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Volume of distribution (Vd) of zilovertamab vedotin Blood samples collected predose and at multiple timepoints postdose will be used to determine Vd of zilovertamab vedotin. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Clearance (CL) of zilovertamab vedotin Blood samples collected predose and at multiple timepoints postdose will be used to determine CL of zilovertamab vedotin. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Apparent terminal half-life (t½) of plasma concentration of zilovertamab vedotin Blood samples collected predose and at multiple timepoints postdose will be used to determine t1/2 of plasma concentration of zilovertamab vedotin. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Cmax of total UC-961 antibody Blood samples collected predose and at multiple timepoints postdose will be used to determine Cmax of total UC-961 antibody. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Tmax of total UC-961 antibody Blood samples collected predose and at multiple timepoints postdose will be used to determine Tmax of total UC-961 antibody. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary AUC of total UC-961 antibody Blood samples collected predose and at multiple timepoints postdose will be used to determine AUC of total UC-961 antibody. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Vd of total UC-961 antibody Blood samples collected predose and at multiple timepoints postdose will be used to determine Vd of total UC-961 antibody. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary CL of total UC-961 antibody Blood samples collected predose and at multiple timepoints postdose will be used to determine CL of total UC-961 antibody. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary t1/2 of plasma concentration of total UC-961 antibody Blood samples collected predose and at multiple timepoints postdose will be used to determine t1/2 of plasma concentration of total UC-961 antibody. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Cmax of MMAE Blood samples collected predose and at multiple timepoints postdose will be used to determine Cmax of MMAE. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Tmax of MMAE Blood samples collected predose and at multiple timepoints postdose will be used to determine Tmax of MMAE. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary AUC of MMAE Blood samples collected predose and at multiple timepoints postdose will be used to determine AUC of MMAE. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Vd of MMAE Blood samples collected predose and at multiple timepoints postdose will be used to determine Vd of MMAE. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary CL of MMAE Blood samples collected predose and at multiple timepoints postdose will be used to determine CL of MMAE. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary t1/2 of plasma concentration of MMAE Blood samples collected predose and at multiple timepoints postdose will be used to determine t1/2 of plasma concentration of MMAE. Cycle 1 Day 1, 2, 3, 8, 15: predose, end of infusion (up to 4 hours); Day 1, Day 8 (Schedule 2, 3), Day 15 (Schedule 3) of Cycles 2 through end of therapy (up to ~3.5 years): predose, end of infusion
Secondary Number of participants with zilovertamab vedotin-reactive antibodies Number of participants with zilovertamab vedotin-reactive antibodies will be assessed. Day 1 of Cycles 1 through end of therapy (up to approximately 3.5 years): predose and end of infusion (up to ~30 minutes)
Secondary Overall Response (OR) OR will be defined by achievement of the following outcomes as indicated by disease type: CLL/SLL: Complete response (CR: disappearance of detectable disease per Cheson 2012 criteria), CR with incomplete blood count recovery (CRi: CR with =1 additional change in absolute neutrophil count, platelet count, or hemoglobin), partial response (PR: no evidence of new disease per Cheson 2012 criteria), or PR with lymphocytosis (PR except lack of decrease in peripheral blood absolute lymphocyte count); NHL: CR (disappearance of all detectable disease per Cheson 2014 criteria) or PR (=50% decrease in the sum of the product of diameters of the index nodal and extranodal lesions); LPL/WM: CR, very good PR (CR with =90% decrease in M protein), PR, or minor response (criteria for PR or stable disease met per Cheson 2014); ALL: (CR, CRi, unconfirmed CR, or PR per National Comprehensive Cancer Network criteria); AML (CR, CRi, morphologic leukemia-free state [MLFS], or PR per Cheson 2003 criteria). Up to approximately 3.5 years
Secondary Complete Response without measurable residual disease (CRMRD-) CRMRD- is defined as the achievement of =1 × 10^-4 malignant cells in bone marrow (as assessed by flow cytometry) in a participant who meets all other criteria for CR. Up to approximately 3.5 years
Secondary Percent change from baseline in tumor dimension Percent change in tumor dimensions is defined as the percent change from baseline in the sum of the products of the diameters (SPD) of index lesions. Up to approximately 3.5 years
Secondary Time to Response (TTR) TTR is defined as the interval from the start of study therapy to the first documentation of an objective response. Up to approximately 3.5 years
Secondary Duration of Response (DOR) DOR is defined as the interval from the first documentation of objective response to the earlier of the first documentation of disease progression/relapse or death from any cause. Up to approximately 3.5 years
Secondary Progression free survival (PFS) PFS is defined as the interval from the start of study therapy to the earlier of the first documentation of disease progression/relapse or death from any cause. Up to approximately 3.5 years
Secondary Time to Treatment Failure (TTF) TTF failure is defined as the interval from start of study therapy to the earliest of the first documentation of disease progression/relapse, treatment failure (for participants with ALL or AML), the permanent cessation of study drug due to an AE, or death from any cause. Up to approximately 3.5 years
Secondary Overall Survival (OS) OS is defined as the interval from the start of study therapy to death from any cause. Up to approximately 3.5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2